**Supplementary Data**

**Supplementary Table 1. Antitumor activity**

|  |  |
| --- | --- |
|  | **Avelumab dose** |
| **3 mg/kg****Q2W****(n=3)** | **10 mg/kg****Q2W****(n=7)** | **20 mg/kg****Q2W****(n=6)** | **10 mg/kg****QW→Q2W****(n=8)** | **Total****(N=24)** |
| **BOR, n (%)**CRPRSDPDNE | 002 (66.7)1 (33.3)0 | 003 (42.9)4 (57.1)0 | 01 (16.7)2 (33.3)3 (50.0)0 | 00 2 (25.0)a4 (50.0)2 (25.0) | 01 (4.2)9 (37.5)12 (50.0)2 (8.3) |
| **Confirmed ORR, n (%) [95% CI]** | 0[0.0, 70.8] | 0[0.0, 41.0] | 1 (16.7)[0.4, 64.1] | 0[0.0, 36.9] | 1 (4.2)[0.1, 21.1] |
| **Confirmed DCR, n (%)** | 2 (66.7) | 3 (42.9) | 3 (50.0) | 2 (25.0) | 10 (41.7) |
| **Median PFS (95% CI), months** | 6.9 (1.4, NE) | 2.6 (1.3, 5.5) | 3.5 (0.9, NE) | 1.3 (1.3, NE) | 1.9 (1.3, 5.5) |
| **Median OS (95% CI), months** | NE (NE, NE) | NE (1.3, NE) | NE (1.3, NE) | NE (2.8, NE) | NE (9.6, NE) |

a Unconfirmed PR reported in 1 patient.

Abbreviations: BOR, best overall response; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; Q2W, every 2 weeks; QW, every week; SD, stable disease.